Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | BCL2L11 | O43521 | 2/20 | 0.37 |
| ▸ | BCL2 | P10415 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4892395 | 0.91 | DPP4 (0.41) | DPP4DPP7BCL2L11BCL2MCL1 | |
| SCHEMBL4896667 | 0.89 | DPP4 (0.40) | DPP4DPP7BCL2L11BCL2MCL1 | |
| SCHEMBL4892589 | 0.88 | DPP4 (0.41) | DPP4DPP7BCL2L11BCL2MCL1 | |
| SCHEMBL4891522 | 0.88 | DPP4 (0.41) | DPP4DPP7BCL2L11BCL2MCL1 | |
| Hydrochloric Acid SCHEMBL4889951 | 0.88 | DPP4 (0.43) | DPP4DPP7BCL2L11BCL2MCL1 | |
| SCHEMBL4890000 | 0.86 | DPP4 (0.42) | DPP4DPP7DPP8 | |
| SCHEMBL4893398 | 0.86 | DPP4 (0.43) | DPP4DPP7DPP8 | |
| SCHEMBL4894815 | 0.85 | DPP4 (0.41) | DPP4DPP7BCL2L11BCL2MCL1 | |
| SCHEMBL4899287 | 0.85 | DPP4 (0.39) | DPP4DPP7BCL2L11BCL2MCL1 | |
| SCHEMBL4895049 | 0.82 | DPP4 (0.47) | DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | claimed |
| EP-1758863-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | AstraZeneca AB (SE) | 2007-03-07 | — | — | EP | claimed |
| WO-2005123685-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | claimed |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | DPP4 1/4885DPP7 4/4885BCL2L11 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.